Roukos D, Schmidt-Mathiesen A, Encke A
Department of Surgery, University of Ioannina, Greece.
Surg Oncol. 1995;4(6):323-32. doi: 10.1016/s0960-7404(10)80045-3.
The purpose of this retrospective study was to evaluate whether a more radical resection, including total gastrectomy (TG), D2 lymphadenectomy and splenectomy, or subtotal gastrectomy (SG), improves the prognosis of patients with an adenocarcinoma located on the distal third of the stomach.
Seventy-four consecutive patients with an antral carcinoma underwent gastric resection. Forty-three had a TG and 31 an SG. D2 lymph node dissection was carried out in 70% of all patients (30/43) and 100% (21/21) of patients with curative resection in the TG group, whereas in the SG group the patients had only a standard D1 lymph node dissection. Splenectomy was carried out in 84% (36/43) of patients in the TG group, whereas in the SG group the spleen was preserved in all patients. Follow-up was complete for 100% of the patients, with a median follow-up time of 74 months. MAIN END-POINTS OF INTEREST: Overall survival rates, mortality and morbidity rates.
The postoperative 30-day mortality rate was 7% in the TG group and 3.2% in the SG group. The overall morbidity rate was increased from 19% after SG to 37% after TG. There was no microscopic evidence of involvement of proximal resection margins in any of 31 subtotal resected gastric specimens. Lymph node metastases to the splenic hilus (no. 10 nodes) or along the splenic artery (no. 11 nodes) were not found in any of 36 patients who underwent splenectomy and lymphadenectomy. The 5- or 10-year survival rates did not differ significantly between both groups. Analysis of survival showed no significant difference between the TG and SG groups when related to subgroups of patients with curative resection (UICC-RO resection), nodal status (pN), tumour depth (pT-category), tumour stage (pTNM), or Lauren classification (intestinal or diffuse type of carcinoma). The survival rates for patients with curative resection after 5 or 10 years were 58% in the TG group and 66% or 51% in SG group, respectively (P = 0.66).
Since D2 total gastrectomy carried an increased overall morbidity risk and did not improve survival in patients with intestinal or diffuse type carcinoma, it seems that with regard to luminal gastric resection, SG is the treatment of choice for carcinomas located in the distal third of the stomach. Whether extensive radical D2 lymphadenectomy should be routinely performed in addition to SG is still controversial.The spleen should be preserved in most cases.
本回顾性研究旨在评估更彻底的切除术,包括全胃切除术(TG)、D2淋巴结清扫术和脾切除术,或次全胃切除术(SG),是否能改善位于胃远端三分之一处腺癌患者的预后。
74例连续的胃窦癌患者接受了胃切除术。43例行TG,31例行SG。70%(30/43)的患者和TG组100%(21/21)行根治性切除的患者进行了D2淋巴结清扫,而SG组患者仅进行了标准的D1淋巴结清扫。TG组84%(36/43)的患者进行了脾切除术,而SG组所有患者均保留脾脏。所有患者均完成随访,中位随访时间为74个月。主要观察终点:总生存率、死亡率和发病率。
TG组术后30天死亡率为7%,SG组为3.2%。总体发病率从SG术后的19%增加到TG术后的37%。31例次全切除胃标本中,无一例在显微镜下有近端切缘受累的证据。36例行脾切除术和淋巴结清扫术的患者中,无一例发现脾门淋巴结转移(第10组淋巴结)或沿脾动脉的淋巴结转移(第11组淋巴结)。两组的5年或10年生存率无显著差异。生存分析显示,与根治性切除(UICC-RO切除)、淋巴结状态(pN)、肿瘤深度(pT分类)、肿瘤分期(pTNM)或Lauren分类(肠型或弥漫型癌)的患者亚组相关时,TG组和SG组之间无显著差异。TG组根治性切除患者5年和10年后的生存率分别为58%,SG组分别为66%或51%(P = 0.66)。
由于D2全胃切除术总体发病风险增加,且未改善肠型或弥漫型癌患者的生存率,因此对于胃腔切除术而言,SG似乎是胃远端三分之一处癌的首选治疗方法。除SG外是否应常规进行广泛的根治性D2淋巴结清扫仍存在争议。大多数情况下应保留脾脏。